Format

Send to

Choose Destination
AIDS. 2013 Nov;27 Suppl 2:S207-13. doi: 10.1097/QAD.0000000000000095.

Linkage, initiation and retention of children in the antiretroviral therapy cascade: an overview.

Author information

1
aUnited States Agency for International Development, Washington, District of Columbia bBaylor College of Medicine, Houston, Texas cUnited States Agency for International Development, Washington, District of Columbia dCenters for Disease Control and Prevention, Atlanta, Georgia eManagement Sciences for Health, Washington, District of Columbia fBaylor College of Medicine, Houston, Texas gClinton Health Access Initiative, New York, New York hLiverpool School of Tropical Medicine, UK. *B. Ryan Phelps, Saeed Ahmed, Anouk Amzel, Mamadou O. Diallo, Troy Jacobs, Scott E. Kellerman, Maria H. Kim, Nandita Sugandhi, and Melanie Tam contributed equally to the writing of the article.

Abstract

In 2012, there were an estimated 2 million children in need of antiretroviral therapy (ART) in the world, but ART is still reaching fewer than 3 in 10 children in need of treatment. [1, 7] As more HIV-infected children are identified early and universal treatment is initiated in children under 5 regardless of CD4, the success of pediatric HIV programs will depend on our ability to link children into care and treatment programs, and retain them in those services over time. In this review, we summarize key individual, institutional, and systems barriers to diagnosing children with HIV, linking them to care and treatment, and reducing loss to follow-up (LTFU). We also explore how linkage and retention can be optimally measured so as to maximize the impact of available pediatric HIV care and treatment services.

PMID:
24361630
PMCID:
PMC4124132
DOI:
10.1097/QAD.0000000000000095
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center